Heidelberg, November 06, 2008 – SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today announced that it has raised approx. 18.3 mn euros through a capital increase. In total SYGNIS sold 12,694,967 newly issued shares from authorized capital at a price of 1.44 euros and at an exchange ratio of 9:4 to existing shareholders. With the placement of the additional shares, SYGNIS’ total registered share capital will increase from 28,563,676.00 euros to 41,258,643.00 euros.
The listing of the new shares on the Frankfurt Stock Exchange is expected to take place by December 2008. As result of the capital increase, the freefloat of the company will decrease on a diluted basis to approx. 42 %, the stake of Bayer AG to approx. 3% and the stake of Dr. Friedrich von Bohlen und Halbach to approx 5%. SYGNIS’ largest shareholders dievini Hopp BioTech holding GmbH & Co. KG and BASF SE will increase to approx. 36% and 13%.
On November 12, 2008, the company will publish its half year report of fiscal year 2008/2009.
About SYGNIS Pharma
SYGNIS Pharma AG, headquartered in Heidelberg, is a specialty pharmaceutical company listed on the Prime Standard of the German stock exchange. The Company is focused on the research, development and marketing of innovative therapies for the treatment of disorders of the Central Nervous System. These include Stroke, Amyotrophic Lateral Sclerosis and neurological disorders resulting from injuries to the brain or spinal cord. All these disorders are characterized by the fact that, as the disease progresses, nerve cells are damaged and die. Although there is great medical demand, there are currently no or only inadequate treatment options available.
One of the central elements in this value-creation chain is the continued development of the existing product pipeline. This is achieved by testing the Company’s proprietary compounds which are already under development in a number of further CNS indications (“line extension”). By means of specific R&D programs at SYGNIS, new pre-clinical drug candidates are identified and evaluated and suitable CNS product candidates are also systematically tested for the purpose of acquisition or in-licensing.
For further information please contact:
SYGNIS Pharma AG: Dr. Franz-Werner Haas Vice President Operations +49 (0) 6221 454 812 franz-werner.haas@sygnis.de
Media-Contact: Julia Phillips Financial Dynamics Tel.: +44 (0) 20 7269 7187
